Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Graefe's Archive for Clinical and Experimental Ophthalmology

• Publication date

  2010-02-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00417-010-1303-3PMID 20135139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

  2009cited by this paper
• Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up.

  2008cited by this paper
• Bevacizumab Suppresses Choroidal Neovascularization Caused by Pathological Myopia

  2008cited by this paper
• Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

  2008cited by this paper
• Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)

  2008cited by this paper
• Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series

  2008cited by this paper
• Bevacizumab (Avastin) for the treatment of neovascular glaucoma

  2007cited by this paper
• Our Experience After 1765 Intravitreal Injections of Bevacizumab: The Importance of Being Part of a Developing Story

  2007cited by this paper
• Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

  2007cited by this paper
• Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.

  2007cited by this paper
• Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

  2007cited by this paper
• Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

  2007cited by this paper
• Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006cited by this paper
• Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.

  2006cited by this paper
• VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS

  2006cited by this paper
• Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy.

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)

  2006cited by this paper
• Intravitreal Bevacizumab (Avastin) Treatment of Macular Edema in Central Retinal Vein Occlusion

  2006cited by this paper
• Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

  2006cited by this paper
• Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

  2006cited by this paper
• Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.

  2006cited by this paper
• Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.

  2006cited by this paper
• Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

  2006cited by this paper
• DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE

  2006cited by this paper
• Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

  2005cited by this paper
• Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

  2005cited by this paper
• Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

  2005cited by this paper
• Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

  2005cited by this paper
• The role of bevacizumab as first-line therapy for colon cancer.

  2005cited by this paper
• THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE

  2005cited by this paper
• Pegaptanib for neovascular age-related macular degeneration.

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2004cited by this paper
• Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

  2003cited by this paper
• Candidate-gene approaches for studying complex genetic traits: practical considerations

  2002cited by this paper
• Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

  2002cited by this paper
• Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes.

  2002cited by this paper
• Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.

  2000cited by this paper
• RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS

  1999cited by this paper
• Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.

  1998cited by this paper
• Increased expression of angiogenic growth factors in age-related maculopathy

  1997cited by this paper
• Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.

  1996cited by this paper
• Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.

  1996cited by this paper
• Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

  1995cited by this paper
• Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy

  1995cited by this paper
• Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

  1994cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper

• Perioperative anti-VEGF therapy for proliferative diabetic retinopathy: a network meta-analysis of RCTs.

  2026cites this paper
• Timing of Preoperative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy: A Competing-Risks Analysis of a Large Cohort.

  2025cites this paper
• Intravitreal anti-vascular endothelial growth factor agents as an adjunct for proliferative diabetic retinopathy: a systematic review and meta-analysis

  2025cites this paper
• Bevacizumab and beyond: investigating the role of combination therapies in the management of retinal diseases

  2025cites this paper
• Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.

  2023cites this paper
• Appropriate timing schedule for intravitreal anti-VEGF injection as adjuvant therapy before pars-plana vitrectomy in proliferative diabetic retinopathy, a meta analysis

  2023cites this paper
• Systemic complications of intravitreal bevacizumab: a case report and literature review

  2023cites this paper
• Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial

  2023cites this paper
• Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy

  2023cites this paper
• Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

  2023cites this paper
• VITRECTOMY FOR DIABETIC COMPLICATIONS

  2022influential citation
• Advances in Vitreoretinal Surgery

  2022cites this paper
• MiR-191 inhibits retinal neovascularization by regulating CDK6, cyclin D1, P21 expression and restoring energy metabolism.

  2022cites this paper
• Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients

  2022cites this paper
• Angiogenic footprints in diabetic retinopathy: opportunities for drug development

  2022cites this paper
• Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy

  2021cites this paper
• Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: a systematic review

  2021cites this paper
• Anti-VEGF Crunch Syndrome in Proliferative Diabetic Retinopathy: A Review.

  2021cites this paper
• Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti‐vascular endothelial growth factor therapy for proliferative diabetic retinopathy

  2021cites this paper
• Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy

  2021cites this paper
• Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy

  2020cites this paper
• Prognostic factors of revitrectomy for complications in eyes with proliferative diabetic retinopathy: a retrospective multicentre study

  2020cites this paper
• The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy

  2020cites this paper
• Effect of Intrasilicone Bevacizumab Injection in Diabetic Tractional Retinal Detachment Surgery: A Retrospective Case-Control Study

  2020cites this paper
• Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy

  2019cites this paper
• Bimanual Pars Plana Vitrectomy for Diabetic Tractional Retinal Detachment

  2019cites this paper
• Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab

  2019cites this paper
• Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy

  2019cites this paper
• Vitreous Base Shaving in Diabetic Vitreous Haemorrhage

  2019cites this paper
• OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection

  2019cites this paper
• Surgical management of diabetic tractional retinal detachments.

  2019cites this paper
• Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

  2018cites this paper
• 5-Fluorouracyl added infusion fluid in patients with recurrent rhegmatogeneous retinal detachment

  2018cites this paper
• Bevacizumab as an adjunct to vitrectomy for diabetic retinopathy: A retrospective study

  2018cites this paper
• Vitreous rebleed following sutureless vitrectomy: Incidence and risk factors

  2018cites this paper
• Chapter 7 – Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Eye Disease

  2018cites this paper
• Predictive clinical features and efficacy of preoperative anti-VEGF treatment on visual acuity in patients with proliferative diabetic retinopathy

  2018influential citation
• Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy

  2018cites this paper
• The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy

  2018cites this paper
• Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

  2018cites this paper
• Current management of diabetic tractional retinal detachments

  2018cites this paper
• Targeting Vascular Endothelial Growth Factor

  2017cites this paper
• Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.

  2017cites this paper
• Title Succinate Increases in the Vitreous Fluid of Patients With ActiveProliferative Diabetic Retinopathy

  2017cites this paper
• Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)

  2017cites this paper
• Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors (for Louisiana Only) – Community Plan Medical Benefit Drug Policy

  2017cites this paper
• Recent advances in the management and understanding of diabetic retinopathy

  2017cites this paper
• Surgical Management and Techniques.

  2017cites this paper
• Demographic features and visual outcomes of patients presenting to diabetic photo-screening and treated for sight threatening retinopathy in Fiji.

  2017cites this paper
• Twenty-seven-gauge vitrectomy for combined tractional and rhegmatogenous retinal detachment involving the macula associated with proliferative diabetic retinopathy

  2017cites this paper
• Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.

  2017cites this paper
• Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.

  2017cites this paper
• The Role of Perioperative Anti-VEGF During Vitrectomy for Vitreous Hemorrhage in Relation to Postoperative Nonclearing Vitreous Hemorrhage and Cystoid Macular Edema

  2017cites this paper
• Review and update of cataract surgery in the diabetic eye

  2017influential citation
• Ranibizumab pre-treatment in Diabetic Vitrectomy - a pilot randomised controlled trial study)

  2017cites this paper
• Surgery for Proliferative Diabetic Retinopathy: New Tips and Tricks

  2016cites this paper
• The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy

  2016cites this paper
• Role of bevacizumab in the prevention of early postoperative haemorrhage after 25-gauge microincision vitrectomy surgery

  2016cites this paper
• Surgical Management of Tractional Retinal Detachments in Proliferative Diabetic Retinopathy

  2016cites this paper
• Effect of Intravitreal Anti-VEGF Therapy on the Severity of Diabetic Retinopathy

  2016cites this paper
• The Effect of Bevacizumab Pretreatment on the Choice of Endotamponade in Diabetic Tractional Retinal Detachment.

  2016cites this paper
• Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment

  2016cites this paper
• INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY

  2016cites this paper
• A Systematic Review of Clinical Studies Using VEGF Inhibitors in the Treatment of Macular Edema from Diabetic Retinopathy

  2016cites this paper
• Intravitreal Angiogenesis Inhibitors for Retinal Vascular Conditions Description

  2015cites this paper
• RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY

  2015cites this paper
• ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis

  2015cites this paper
• Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis

  2015cites this paper
• Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.

  2015cites this paper
• Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

  2015cites this paper
• Clinical outcomes of ranibizumab treatment in diabetic eye disease

  2015cites this paper
• A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy.

  2014cites this paper
• Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era

  2014cites this paper
• Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease--a possible side effect?

  2014cites this paper
• Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy

  2014cites this paper
• ROLE OF AVASTIN ON THE INCIDENCE OF POST OPERATIVE VITREOUS HEMORRHAGE AFTER VITREC- TOMY IN DIABETIC VITREOUS HEMORRHAGE

  2014cites this paper
• Bevacizumab and Diabetic Vitrectomy

  2014cites this paper
• Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

  2014influential citation
• Intravitreal Angiogenesis Inhibitors for Retinal Vascular Conditions

  2014cites this paper
• [Does preoperative intravitreal bevacizumab reduce complications of vitrectomy for proliferative diabetic retinopathy?].

  2014cites this paper
• SURGICAL OUTCOMES OF FLORID DIABETIC RETINOPATHY TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR

  2014cites this paper
• Outcomes of Vitrectomy for Tractional Retinal Detachment in Diabetic Retinopathy

  2014cites this paper
• Increased intravitreous interleukin-18 correlated to vascular endothelial growth factor in patients with active proliferative diabetic retinopathy

  2014cites this paper
• The Role of Intraoperative Bevacizumab for Prevention of Postoperative Vitreous Hemorrhage in Diabetic Vitreous Hemorrhage

  2014cites this paper
• Chapter 111 – Surgery for Proliferative Diabetic Retinopathy

  2013cites this paper
• VITRECTOMY AND PANRETINAL PHOTOCOAGULATION REDUCES THE OCCURRENCE OF NEOVASCULAR GLAUCOMA IN CENTRAL RETINAL VEIN OCCLUSION WITH VITREOUS HEMORRHAGE

  2013cites this paper
• Evolving Strategies in the Management of Diabetic Retinopathy

  2013cites this paper
• Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.

  2013cites this paper
• Contemporary Management of Diabetic Retinopathy in Canada: From Guidelines to Algorithm Guidance

  2013cites this paper
• Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy.

  2013cites this paper
• Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.

  2013cites this paper
• Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa

  2013cites this paper
• Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy

  2013cites this paper
• Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α

  2012cites this paper
• An Overview of Diabetic Retinopathy

  2012cites this paper
• The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy

  2012cites this paper
• Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.

  2012cites this paper
• Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy.

  2012cites this paper
• Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.

  2012cites this paper
• Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy

  2012cites this paper